UCB (EBR:UCB) UCB Media Room: Acquisition of own shares
Transparency directive : regulatory news
12/04/2024 20:00
https://u7061146.ct.sendgrid.net/ls/click?upn=3Du001.gqh-2BaxUzlo7XKIuSly0r=
CyBv9bezcPT-2BuItTLKIHepbxTbo-2FYbVFPSBekB-2Bmk9X7Kl8shoTE6BsSbYYjHYcOVCrOC=
rjYrJUHPDVbu1NKaBE-3Dxz73_2dCLUNbuBjhX746-2FvM63L9Hyn3KnTFGM-2BPPGCjZgmJl-2=
FKl1Z2nt-2BIfez2IJ0TSaz3mplcEW6ZopJ4gUd4Ia3MTdQeFO93DwfIxs8cV3s33SbkEZvEGLN=
n-2B6FohpNoV33Er2gDQt7VZGVSwkJ714ZGJd-2BJhjw0OltVPiJAX1XLKdhqHDTmPxho3eG191=
cg9PY5gugHQ0hY4uze0TYr6jye1l4pmoIzXtnHbbh58Hbmka3YSN65Q08gQRpmwwA-2FkTka0LB=
fHxuRn7Gdp5hCr8LLeSEdBdRSP76cQkrP8t7NX0T-2BlhqDvbRgSFZM-2FZ2Uzn7LAD0UI-2Fw9=
yVFhkjFySkPslswOyPH8FZD2JKnwzpDYYk-3D
** Acquisition of own shares
------------------------------------------------------------
Brussels (Belgium), 12 April 2024 =E2=80=93 20:00 (CEST) =E2=80=93 Regulate=
d information
=C2=A0
Acquisition of own shares
In accordance with article 8:4 of the Royal Decree of 29 April 2019 executi=
ng the Belgian Code on Companies and Associations, UCB SA/NV (=E2=80=9CUCB=
=E2=80=9D or the =E2=80=9CCompany) (Euronext Brussels: UCB) hereby disclose=
s certain information in relation to its Share Repurchase Program 2024.=C2=
=A0
Under this program, UCB has requested a financial intermediary to repurchas=
e up to 1,300,000 UCB shares on its behalf under the terms of a discretiona=
ry mandate agreement with initial validity until 30 June 2024, effective as=
from 02 April 2024, to cover current and future obligations under UCB's Lo=
ng Term Incentive Plans for its personnel.
In the framework of this Share Repurchase Program 2024, UCB repurchased 112=
,680 UCB shares on Euronext Brussels in the period from 05 April 2024 up to=
and including 11 April 2024, as follows:=C2=A0
https://u7061146.ct.sendgrid.net/ls/click?upn=3Du001.gqh-2BaxUzlo7XKIuSly0r=
CyBv9bezcPT-2BuItTLKIHepbtZNcDtG8Y2MhOGwqLBpzbfzCabMxn-2BYlAjPsA7EoHI63-2BG=
ps0KzdM1wiqBQq3Px8hsVRdz9QPCskoFaO6dwy6vT9d_2dCLUNbuBjhX746-2FvM63L9Hyn3KnT=
FGM-2BPPGCjZgmJl-2FKl1Z2nt-2BIfez2IJ0TSaz3mplcEW6ZopJ4gUd4Ia3MTdQeFO93DwfIx=
s8cV3s33SbkEZvEGLNn-2B6FohpNoV33Er2gDQt7VZGVSwkJ714ZGJd-2BJhjw0OltVPiJAX1XL=
KdhqHDTmPxho3eG191cg9PY5gugHQ0hY4uze0TYr6jye4tTE2Jvt7BcFxR101amolnLqT1TSDvj=
UAFsy2Ym-2FehCAOSyOMdsDHocrqayUq28zzywecpEizzYa4h7uwaXTtcR7vbOe-2FBaiHeW493=
JY4We7jkqaC3Nn8LPqqkYqhzAd1iSeWs8xaNG4Wf4Kq46Eog-3D
This press release is available on UCB SA/NV=E2=80=99s website via the foll=
owing link (https://u7061146.ct.sendgrid.net/ls/click?upn=3Du001.gqh-2BaxUz=
lo7XKIuSly0rC4Oa12rFuiaXNgb0F6L7ybSCidGRlUFwTxzrkzCt6dOMzdZPcjqPbg8jratFLJj=
fTg-3D-3DpmFa_2dCLUNbuBjhX746-2FvM63L9Hyn3KnTFGM-2BPPGCjZgmJl-2FKl1Z2nt-2BI=
fez2IJ0TSaz3mplcEW6ZopJ4gUd4Ia3MTdQeFO93DwfIxs8cV3s33SbkEZvEGLNn-2B6FohpNoV=
33Er2gDQt7VZGVSwkJ714ZGJd-2BJhjw0OltVPiJAX1XLKdhqHDTmPxho3eG191cg9PY5gugHQ0=
hY4uze0TYr6jyexhtrv9sQtWBUbw-2FSd-2F-2FvN68Vf42uhOAaO6HAAIl3F6OVcfknAbxWkqW=
duWi4Y2MjVMnFKBcqn2t2HnKuTLLGUFuw0KpzdsMmoEaFeBM7kDkJncYekojwnQU0fXfNF98f-2=
B1QH5Cak1sKI5RkrxqafLU-3D .
For further information, contact UCB:=C2=A0
Investor Relations
Antje Witte=C2=A0
T +32 2 559 94 14
Antje.Witte@ucb.com
Corporate Communications
Laurent Schots=C2=A0
T+32 2 559 92 64
laurent.schots@ucb.com =C2=A0=C2=A0 =C2=A0
About UCB
UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company =
focused on the discovery and development of innovative medicines and soluti=
ons to transform the lives of people living with severe diseases of the imm=
une system or of the central nervous system. With approximately 9,000 peopl=
e in approximately 40 countries, the company generated revenue of =E2=82=AC=
5.3 billion in 2023. UCB is listed on Euronext Brussels (symbol: UCB). Foll=
ow us on Twitter: @UCB_news.
=C2=A0
GenericFile
240412 - Acquisition actions propres FR Final (https://u7061146.ct.sendgrid=
.net/ls/click?upn=3Du001.gqh-2BaxUzlo7XKIuSly0rCyBv9bezcPT-2BuItTLKIHepbtZN=
cDtG8Y2MhOGwqLBpzb1gPmvBt-2FSw4Oh-2BLPbNJzKG35lTTsG47hcah3iDOP-2BC0-3D4hZm_=
2dCLUNbuBjhX746-2FvM63L9Hyn3KnTFGM-2BPPGCjZgmJl-2FKl1Z2nt-2BIfez2IJ0TSaz3mp=
lcEW6ZopJ4gUd4Ia3MTdQeFO93DwfIxs8cV3s33SbkEZvEGLNn-2B6FohpNoV33Er2gDQt7VZGV=
SwkJ714ZGJd-2BJhjw0OltVPiJAX1XLKdhqHDTmPxho3eG191cg9PY5gugHQ0hY4uze0TYr6jye=
yQ9JboJjHbaxQmTK9kYuUcx16-2Fto85xAR8N-2FvuCXMdmstYf5SdJEvd7FAVLI1iI1KVtz7Va=
nYpg-2FBHuOp8KSAttZnCZ2IvivgNwKY5xN7rfaLcHun5YEWF8-2F5Mnx7W-2BEryN4FQISW44A=
1-2BIBTbF6CQ-3D GenericFile
240412 - Verwerving van eigen aandelen NL Final (https://u7061146.ct.sendgr=
id.net/ls/click?upn=3Du001.gqh-2BaxUzlo7XKIuSly0rCyBv9bezcPT-2BuItTLKIHepbt=
ZNcDtG8Y2MhOGwqLBpzb8xpYi-2F4jmbyBzBzlyrFIvbm1vn8ooD-2F24lO9DWycEgY-3Dsdfg_=
2dCLUNbuBjhX746-2FvM63L9Hyn3KnTFGM-2BPPGCjZgmJl-2FKl1Z2nt-2BIfez2IJ0TSaz3mp=
lcEW6ZopJ4gUd4Ia3MTdQeFO93DwfIxs8cV3s33SbkEZvEGLNn-2B6FohpNoV33Er2gDQt7VZGV=
SwkJ714ZGJd-2BJhjw0OltVPiJAX1XLKdhqHDTmPxho3eG191cg9PY5gugHQ0hY4uze0TYr6jye=
z3AuCx-2FxyzsgzDDCI4eG8THlZxXMnJfHyVo-2Bw-2FT4uHMQcqAwjlB-2FqNGuB193ivRuD1R=
jGwmt880Sqn5Z09ft9-2Bg5AU4xJZJ9gFf92EAcBXI2yVH-2FEVCpHravyMguw0MxGtIyb0ajWH=
wHd-2FuO8d65XY-3D GenericFile
240412 - Acquisition of own shares ENG Final (https://u7061146.ct.sendgrid.=
net/ls/click?upn=3Du001.gqh-2BaxUzlo7XKIuSly0rCyBv9bezcPT-2BuItTLKIHepbtZNc=
DtG8Y2MhOGwqLBpzboeCx5Shqlw-2BD47EWFRfPlDk2E6oMVWDI6iQ1R-2FtHl74-3D9SUx_2dC=
LUNbuBjhX746-2FvM63L9Hyn3KnTFGM-2BPPGCjZgmJl-2FKl1Z2nt-2BIfez2IJ0TSaz3mplcE=
W6ZopJ4gUd4Ia3MTdQeFO93DwfIxs8cV3s33SbkEZvEGLNn-2B6FohpNoV33Er2gDQt7VZGVSwk=
J714ZGJd-2BJhjw0OltVPiJAX1XLKdhqHDTmPxho3eG191cg9PY5gugHQ0hY4uze0TYr6jye-2F=
EPjA7BvMyWFRgTtYGZvlN0uAcpN5TvoqgHODRp3Ry6QHZVcdv96KSEvmhnOUOXtSKBtsjUWmeQA=
M4yzjHppQd6TiDyZqYS6YgNjJA4ZWZ9omfqNClK08PEw8WT72b1fc-2FA4g-2BapCbJ0ah-2Fg0=
2zU8A-3D Image
Chart 1 April 12 2024 (https://u7061146.ct.sendgrid.net/ls/click?upn=3Du001=
.gqh-2BaxUzlo7XKIuSly0rCyBv9bezcPT-2BuItTLKIHepbtZNcDtG8Y2MhOGwqLBpzbfzCabM=
xn-2BYlAjPsA7EoHI2aGwGr9MrU-2B9vkTT5Xbo3o-3D4ibl_2dCLUNbuBjhX746-2FvM63L9Hy=
n3KnTFGM-2BPPGCjZgmJl-2FKl1Z2nt-2BIfez2IJ0TSaz3mplcEW6ZopJ4gUd4Ia3MTdQeFO93=
DwfIxs8cV3s33SbkEZvEGLNn-2B6FohpNoV33Er2gDQt7VZGVSwkJ714ZGJd-2BJhjw0OltVPiJ=
AX1XLKdhqHDTmPxho3eG191cg9PY5gugHQ0hY4uze0TYr6jye1vBQI7nSPbuwgpTQioOk1xkooc=
sKebAVavWnSxwC8tNJCsynCGkC1-2FaHmle41mNrNjn9gzTnGy-2B-2Br2plO1Tsax6ka4mXbCr=
k5yrky4z3I3Df3cBWSgEa-2FwUyVaapQbjLXmOXrxPtNORd9xy4HUCfjQ-3D
______________________
If you would rather not receive future communications from UCB SA, please g=
o to https://u7061146.ct.sendgrid.net/ls/click?upn=3Du001.gqh-2BaxUzlo7XKIu=
Sly0rC3nfmD42E6tJ6HwHGmqtXbhtXDlQ2cTEdRpWV-2BrYPIUNb2TKBBlPaLRSZOzusq09mJ2y=
RbI6vLUIO0t28i6O2yv97ekiHBOh7xYAYGrCfirqaLzIzRytZxwK89cX7N74WdRQ7l7nEWK-2BN=
sSHAbkaIMs-3DPfFk_2dCLUNbuBjhX746-2FvM63L9Hyn3KnTFGM-2BPPGCjZgmJl-2FKl1Z2nt=
-2BIfez2IJ0TSaz3mplcEW6ZopJ4gUd4Ia3MTdQeFO93DwfIxs8cV3s33SbkEZvEGLNn-2B6Foh=
pNoV33Er2gDQt7VZGVSwkJ714ZGJd-2BJhjw0OltVPiJAX1XLKdhqHDTmPxho3eG191cg9PY5gu=
gHQ0hY4uze0TYr6jyezEjvENOSQ6KKNTfJX2q0-2BYO1H0mxA7-2BzbkpSO2ub4vrk93VScsmqR=
KPqF0MvMUdBswfnSS-2B-2BOGMkWAayfh3MddJZBsAyoZ6Z9tdv5RjurypTG-2BXRurIQIJmaw7=
0ttd7W6cLiT-2BqBYGvcE761snTS5k-3D
UCB SA, All=C3=A9e de la Recherche, 60 ., Brussels, . B - 1070 Belgium
source : webdisclosure.com